Compare MKSI & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKSI | ARWR |
|---|---|---|
| Founded | 1961 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 9.6B |
| IPO Year | 1999 | 1993 |
| Metric | MKSI | ARWR |
|---|---|---|
| Price | $164.05 | $70.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $154.60 | $63.70 |
| AVG Volume (30 Days) | 857.4K | ★ 2.7M |
| Earning Date | 02-11-2026 | 02-09-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ 820.97 | N/A |
| EPS | ★ 4.12 | N/A |
| Revenue | ★ $3,832,000,000.00 | $829,448,000.00 |
| Revenue This Year | $10.71 | N/A |
| Revenue Next Year | $7.46 | N/A |
| P/E Ratio | $39.88 | ★ N/A |
| Revenue Growth | 8.13 | ★ 23258.15 |
| 52 Week Low | $54.84 | $9.57 |
| 52 Week High | $170.37 | $72.36 |
| Indicator | MKSI | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 70.59 |
| Support Level | $160.00 | $68.00 |
| Resistance Level | $160.78 | $71.30 |
| Average True Range (ATR) | 5.32 | 3.77 |
| MACD | -0.29 | -0.53 |
| Stochastic Oscillator | 73.67 | 83.42 |
MKS Inc formerly, MKS Instruments Inc is engaged in providing instruments, subsystems, and process control systems used to measure, monitor, deliver, and control parameters of manufacturing processes. The company's product portfolio includes instruments, components, and systems required in manufacturing products such as flat panel displays, medical devices, and electronic materials, among others, used in industrial technologies, semiconductors, life and health sciences, and research and defense markets. The company organizes itself into three reportable business segments: Vacuum Solutions, Photonics Solutions, and Materials Solutions. The Vacuum Solutions segment contributes the majority of the company's revenue.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.